Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib

Hiroshi Wataya, Tatsuro Okamoto, Riichiroh Maruyama, Takashi Seto, Koji Yamazaki, Tetsuzo Tagawa, Seiichi Fukuyama, Atsushi Osoegawa, Jiro Ikeda, Munetsugu Nishimura, Takeharu Yamanaka, Yukito Ichinose

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has been reported to have a certain anti-tumor effect in previously treated patients with non-small cell lung cancer (NSCLC). However, the prognostic factors in those patients with and without a positive response to gefitinib treatment remain unclear. A retrospective chart review was performed in 131 advanced NSCLC patients who received 250 mg of gefitinib as either a second-line or even later stage treatment from July 2002 to December 2005. The clinical factors including age, gender, performance status (PS), stage, histology, the number of prior types of chemotherapy, and the response to first-line chemotherapy were analyzed. One and 38 patients experienced a complete and partial response, respectively, to gefitinib treatment with an overall response rate of 30%. The median survival time (MST) of all patients receiving gefitinib treatment was 10 months while the MST was 28 months in the 39 gefitinib responders and 6 months in the 92 non-responders. Among the 39 gefitinib responders, the predominant prognostic factor was found to be the effectiveness of the first-line chemotherapy. The MST of the 20 patients with a response to the first-line chemotherapy was 32 months while the MST of the 19 patients without a response to the chemotherapy was 22 months (p = 0.025). Among the 92 gefitinib non-responders, the predominant prognostic factor was the PS (p < 0.001). The effectiveness of the first-line chemotherapy was therefore found to be a prognostic factor in the gefitinib responders with previously treated NSCLC, while the PS was shown to be a prognostic factor in the gefitinib non-responders.

Original languageEnglish
Pages (from-to)341-345
Number of pages5
JournalLung Cancer
Volume64
Issue number3
DOIs
Publication statusPublished - Jun 1 2009

Fingerprint

Non-Small Cell Lung Carcinoma
Drug Therapy
Therapeutics
Survival
gefitinib
Age Factors
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Histology

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib. / Wataya, Hiroshi; Okamoto, Tatsuro; Maruyama, Riichiroh; Seto, Takashi; Yamazaki, Koji; Tagawa, Tetsuzo; Fukuyama, Seiichi; Osoegawa, Atsushi; Ikeda, Jiro; Nishimura, Munetsugu; Yamanaka, Takeharu; Ichinose, Yukito.

In: Lung Cancer, Vol. 64, No. 3, 01.06.2009, p. 341-345.

Research output: Contribution to journalArticle

Wataya, H, Okamoto, T, Maruyama, R, Seto, T, Yamazaki, K, Tagawa, T, Fukuyama, S, Osoegawa, A, Ikeda, J, Nishimura, M, Yamanaka, T & Ichinose, Y 2009, 'Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib', Lung Cancer, vol. 64, no. 3, pp. 341-345. https://doi.org/10.1016/j.lungcan.2008.09.005
Wataya, Hiroshi ; Okamoto, Tatsuro ; Maruyama, Riichiroh ; Seto, Takashi ; Yamazaki, Koji ; Tagawa, Tetsuzo ; Fukuyama, Seiichi ; Osoegawa, Atsushi ; Ikeda, Jiro ; Nishimura, Munetsugu ; Yamanaka, Takeharu ; Ichinose, Yukito. / Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib. In: Lung Cancer. 2009 ; Vol. 64, No. 3. pp. 341-345.
@article{310e8f7811c74bc38082708ffeb30c80,
title = "Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib",
abstract = "Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has been reported to have a certain anti-tumor effect in previously treated patients with non-small cell lung cancer (NSCLC). However, the prognostic factors in those patients with and without a positive response to gefitinib treatment remain unclear. A retrospective chart review was performed in 131 advanced NSCLC patients who received 250 mg of gefitinib as either a second-line or even later stage treatment from July 2002 to December 2005. The clinical factors including age, gender, performance status (PS), stage, histology, the number of prior types of chemotherapy, and the response to first-line chemotherapy were analyzed. One and 38 patients experienced a complete and partial response, respectively, to gefitinib treatment with an overall response rate of 30{\%}. The median survival time (MST) of all patients receiving gefitinib treatment was 10 months while the MST was 28 months in the 39 gefitinib responders and 6 months in the 92 non-responders. Among the 39 gefitinib responders, the predominant prognostic factor was found to be the effectiveness of the first-line chemotherapy. The MST of the 20 patients with a response to the first-line chemotherapy was 32 months while the MST of the 19 patients without a response to the chemotherapy was 22 months (p = 0.025). Among the 92 gefitinib non-responders, the predominant prognostic factor was the PS (p < 0.001). The effectiveness of the first-line chemotherapy was therefore found to be a prognostic factor in the gefitinib responders with previously treated NSCLC, while the PS was shown to be a prognostic factor in the gefitinib non-responders.",
author = "Hiroshi Wataya and Tatsuro Okamoto and Riichiroh Maruyama and Takashi Seto and Koji Yamazaki and Tetsuzo Tagawa and Seiichi Fukuyama and Atsushi Osoegawa and Jiro Ikeda and Munetsugu Nishimura and Takeharu Yamanaka and Yukito Ichinose",
year = "2009",
month = "6",
day = "1",
doi = "10.1016/j.lungcan.2008.09.005",
language = "English",
volume = "64",
pages = "341--345",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib

AU - Wataya, Hiroshi

AU - Okamoto, Tatsuro

AU - Maruyama, Riichiroh

AU - Seto, Takashi

AU - Yamazaki, Koji

AU - Tagawa, Tetsuzo

AU - Fukuyama, Seiichi

AU - Osoegawa, Atsushi

AU - Ikeda, Jiro

AU - Nishimura, Munetsugu

AU - Yamanaka, Takeharu

AU - Ichinose, Yukito

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has been reported to have a certain anti-tumor effect in previously treated patients with non-small cell lung cancer (NSCLC). However, the prognostic factors in those patients with and without a positive response to gefitinib treatment remain unclear. A retrospective chart review was performed in 131 advanced NSCLC patients who received 250 mg of gefitinib as either a second-line or even later stage treatment from July 2002 to December 2005. The clinical factors including age, gender, performance status (PS), stage, histology, the number of prior types of chemotherapy, and the response to first-line chemotherapy were analyzed. One and 38 patients experienced a complete and partial response, respectively, to gefitinib treatment with an overall response rate of 30%. The median survival time (MST) of all patients receiving gefitinib treatment was 10 months while the MST was 28 months in the 39 gefitinib responders and 6 months in the 92 non-responders. Among the 39 gefitinib responders, the predominant prognostic factor was found to be the effectiveness of the first-line chemotherapy. The MST of the 20 patients with a response to the first-line chemotherapy was 32 months while the MST of the 19 patients without a response to the chemotherapy was 22 months (p = 0.025). Among the 92 gefitinib non-responders, the predominant prognostic factor was the PS (p < 0.001). The effectiveness of the first-line chemotherapy was therefore found to be a prognostic factor in the gefitinib responders with previously treated NSCLC, while the PS was shown to be a prognostic factor in the gefitinib non-responders.

AB - Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has been reported to have a certain anti-tumor effect in previously treated patients with non-small cell lung cancer (NSCLC). However, the prognostic factors in those patients with and without a positive response to gefitinib treatment remain unclear. A retrospective chart review was performed in 131 advanced NSCLC patients who received 250 mg of gefitinib as either a second-line or even later stage treatment from July 2002 to December 2005. The clinical factors including age, gender, performance status (PS), stage, histology, the number of prior types of chemotherapy, and the response to first-line chemotherapy were analyzed. One and 38 patients experienced a complete and partial response, respectively, to gefitinib treatment with an overall response rate of 30%. The median survival time (MST) of all patients receiving gefitinib treatment was 10 months while the MST was 28 months in the 39 gefitinib responders and 6 months in the 92 non-responders. Among the 39 gefitinib responders, the predominant prognostic factor was found to be the effectiveness of the first-line chemotherapy. The MST of the 20 patients with a response to the first-line chemotherapy was 32 months while the MST of the 19 patients without a response to the chemotherapy was 22 months (p = 0.025). Among the 92 gefitinib non-responders, the predominant prognostic factor was the PS (p < 0.001). The effectiveness of the first-line chemotherapy was therefore found to be a prognostic factor in the gefitinib responders with previously treated NSCLC, while the PS was shown to be a prognostic factor in the gefitinib non-responders.

UR - http://www.scopus.com/inward/record.url?scp=67349131649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349131649&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2008.09.005

DO - 10.1016/j.lungcan.2008.09.005

M3 - Article

C2 - 18995926

AN - SCOPUS:67349131649

VL - 64

SP - 341

EP - 345

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -